Skip to content
Open access

Amyloid-PET pipeline choice influences classification of preclinical Alzheimer's disease

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

The findings highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis and highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis.

Abstract

Background

Quantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials. Although the Centiloid (CL) framework provides a common scale, variability persists across processing pipelines, including differences in template/native space, partial volume correction (PVC), and reference region. These choices may influence cut-points, and in turn positivity rates, as well as longitudinal accumulation rates. We examined cut-point estimates and inter-pipeline discordance in a community cohort where many are expected to have early A{beta} deposition.

Methods

We analysed [18F]florbetapir PET/MR data from predominantly cognitively unimpaired (~95%) individuals aged ~71 years at baseline (n=433) and at follow-up (n=328; ~2.4-year interval) in Insight 46 (1946 British birth cohort). Centiloids were derived using the standard pipeline and ten in-house pipelines employing alternative reference regions and PVC in native space. Gaussian mixture modelling estimated cut-points with bootstrapped uncertainty. We assessed A{beta}-discordance across pipelines as a function of standard CLs and examined follow-up CSF A{beta}42/A{beta}40 (n=120) and PET in individuals with discordant baseline classifications.

Results

Baseline cut-points were 10-23 CL across pipelines, classifying 16-25% as A{beta}-positive. Reliable accumulation cut-points were 3.5-6 CL/year, identifying 16-22% as accumulators. Uncertainty varied across pipelines. At baseline, 18% were discordant across PET measures, predominantly between 11-35 standard CLs. The discordant group showed higher A{beta}-PET accumulation and lower CSF A{beta}42/A{beta}40 than concordant negatives.

Conclusions

Disagreement between A{beta}-PET methods was highest between 11-35 standard Centiloids and was frequently associated with accumulating A{beta}. These findings highlight the importance of considering cut-point uncertainty and methodological influences when interpreting early-stage amyloidosis.

Read PDF

Similar papers

Open access Aug 2026

A data-driven regional amyloid PET score predicts cognitive decline beyond Centiloid

Background: The Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity. As a global summary measure, however, CL may not fully reflect the regional distribution of amyloid deposition, which can carry additional prognostic information about the rate of cogniti...

T. Hirose, W. Akamatsu, T. Kato · 0 citations
Sep 2026

Basal Ganglia Perivascular Space Enlargement Is Associated with Sustained Amyloid-β Accumulation in the Alzheimer's Disease Continuum: A Longitudinal Study.

Higher baseline BG-EPVS burden was associated with a more sustained rate of amyloid-β accumulation among participants with high baseline amyloid burden, and the annual rate of change in FBP SUVR follows an inverted U-shaped relationship with baseline FBP SUVR.

Ling-Yun Liu, Qing-Ze Zeng, Xiao Luo et al. · 0 citations
Open access Aug 2026

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al. · 1 citation
Sep 2026

Clinic-based real-world analysis of amyloid PET positivity and MRI markers across subjective cognitive decline, mild cognitive impairment, and early Alzheimer's disease.

BackgroundAlzheimer's disease (AD) is increasingly defined biologically. Amyloid positron emission tomography (PET) is a validated biomarker; however, evidence from truly consecutive, real-world memory-clinic cohorts spanning subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early AD remains limi...

Heii Arai, Satoko Aiba, Hideo Yamamoto et al. · 0 citations
Open access Jul 2026

Lecanemab in symptomatic PSEN1 p.Met233Val early‐onset Alzheimer's disease: Neuroimaging safety, regional amyloid‐PET dynamics, and longitudinal plasma biomarkers

The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.

Min-Young Noh, Wonjae Sung, Hyunkee Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.